AU Patent

AU2017285390B2 — Stable orally disintegrating pharmaceutical compositions

Assigned to Dexcel Pharma Technologies Ltd · Expires 2022-09-29 · 4y expired

What this patent protects

Described herein are stable orally disintegrating tablets containing a proton pump inhibitor, methods for making the same, and methods for treating subjects in need thereof. In particular, the orally disintegrating tablets are composed of a plurality of coated units admixed with …

USPTO Abstract

Described herein are stable orally disintegrating tablets containing a proton pump inhibitor, methods for making the same, and methods for treating subjects in need thereof. In particular, the orally disintegrating tablets are composed of a plurality of coated units admixed with a disintegrant that demonstrate decreased friability and increased hardness.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017285390B2
Jurisdiction
AU
Classification
—
Expires
2022-09-29
Drug substance claim
No
Drug product claim
No
Assignee
Dexcel Pharma Technologies Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.